The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000814370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
17/06/2026
Date registered
Help: Date registered
7/07/2026
Date last updated
Help: Date last updated
7/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Validation of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as a traumatic brain injury (TBI) prognostication marker.
Scientific title
Validation of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) assays as a traumatic brain injury (TBI) prognostication marker
Additional trial identifiers [1] 317572 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Traumatic Brain Injury 342322 0
Trauma 342323 0
Condition category
Condition code
Neurological 338453 338453 0 0
Other neurological disorders
Injuries and Accidents 338753 338753 0 0
Other injuries and accidents

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
a) Overview of information collected
The following data are collected for each participant, drawn from hospital records, ICU registry data (ANZICS/APACHE), and (where applicable) the linked EPO-TRAUMA and PRECISION-TBI datasets:

Demographic and injury data: gender, age, date and time of injury, mechanism of injury, Injury Severity Score (ISS), admission GCS and pupillary score (post-resuscitation), IMPACT-TBI score, history of pre-hospital hypotension/hypoxia, and highest educational level achieved.
Biomarker data: plasma GFAP and UCH-L1 levels from two blood samples (ICU admission and 24 hours post-injury).

Radiological data: CT brain reports (and MRI where performed) confirming presence/absence and predominant type of TBI, plus de-identified CT/MRI image files.
Outcome data: ICU and hospital outcome data and 6-month functional outcomes — Glasgow Outcome Scale–Extended (GOS-E) for all relevant patients and additionally WHO-DAS and EQ-5D-5L for EPO-TRAUMA-linked patients.

b) What is involved for participants
Participant burden is minimal. The study is observational and pragmatic: blood sampling is timed to coincide with routine ICU arterial-line sampling, so little (=10 ml) or no additional blood is drawn beyond routine clinical care. No imaging or other tests are ordered solely for the study. Most data are obtained directly from medical records, registry datasets, and linked trial datasets. The only active participant involvement is a 6-month follow-up telephone interview (with the participant and/or their research decision-maker) to collect functional outcome measures — and for participants already enrolled in EPO-TRAUMA or PRECISION-TBI, even this is obtained via data-sharing agreements rather than a separate contact.

c) Duration of observation
Each participant is observed for 6 months following their traumatic injury — from ICU admission (with biomarker sampling at admission and 24 hours post-injury) through to the 6-month outcome assessment. (A subset of stored blood samples is additionally re-analysed at =1 year and =2.5 years post-collection to assess long-term sample stability.)
Intervention code [1] 334366 0
Diagnosis / Prognosis
Description of the comparator or control
This observational study uses several comparator groups and reference standards rather than a treatment control:

Non-TBI trauma cohort (n=30): trauma patients admitted to ICU/trauma unit without TBI, serving as the comparator for assessing the diagnostic specificity and sensitivity of GFAP and UCH-L1 in distinguishing TBI from non-TBI trauma.

TBI non-survivor cohort (n=10): catastrophically injured TBI patients, compared against the TBI survivor cohort (n=60) to assess the prognostic discrimination of GFAP and UCH-L1.

6-month functional outcome measures (GOS-E and, additionally, WHO-DAS and EQ-5D-5L where available): biomarker levels are correlated against these established outcome standards to evaluate prognostic utility.

International benchmark data: the study's prognostic results are validated by comparison against relevant published international GFAP and UCH-L1 prognostication data, which serves as the gold-standard reference.

No treatment-based control group is used, as this is an observational biomarker validation study with no intervention.
Control group
Active

Outcomes
Primary outcome [1] 345745 0
Ability of plasma GFAP to discriminate traumatic brain injury (TBI) from non-TBI trauma patients.
Timepoint [1] 345745 0
Measured at ICU admission (within 24 hours of injury) and at 24 hours post-injury.
Primary outcome [2] 345957 0
Ability of plasma UCH-L1 to discriminate traumatic brain injury (TBI) from non-TBI trauma patients.
Timepoint [2] 345957 0
Measured at ICU admission (within 24 hours of injury) and at 24 hours post-injury.
Secondary outcome [1] 463132 0
Difference in plasma GFAP and UCH-L1 levels between TBI survivors and TBI non-survivors (mortality stratification; pre-specified as exploratory given the small non-survivor group).
Timepoint [1] 463132 0
Biomarkers measured at ICU admission and 24 hours post-injury; mortality outcome is in-hospital death.
Secondary outcome [2] 463133 0
Correlation between plasma GFAP and UCH-L1 levels and 6-month global functional outcome measured by the Glasgow Outcome Scale – Extended (GOS-E).
Timepoint [2] 463133 0
Biomarkers at ICU admission and 24 hours post-injury; GOS-E assessed at 6 months post-injury.
Secondary outcome [3] 463323 0
Correlation between plasma GFAP and UCH-L1 levels and 6-month disability measured by the World Health Organisation Disability Assessment Schedule 2.0 (WHO-DAS 2.0) total score.
Timepoint [3] 463323 0
Biomarkers at ICU admission and 24 hours post-injury; WHO-DAS 2.0 assessed at 6 months post-injury.
Secondary outcome [4] 463934 0
Independent prognostic contribution of plasma GFAP and UCH-L1 to 6-month functional outcome (GOS-E) and to mortality, after adjustment for pre-specified clinical covariates.
Timepoint [4] 463934 0
Biomarkers at ICU admission (with 24-hour values explored as sensitivity analyses); outcomes at 6 months (GOS-E) and in-hospital (mortality).

Eligibility
Key inclusion criteria
Patients admitted to the ICU who:
1. Are less than 24 hours since suffering from a traumatic brain injury
2. Are expected to stay in the ICU for more than 48 hours
3. Are between 18 and 80 years old
4. Have CT brain imaging evidence of presence of traumatic brain injury
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Conditions which will cause a rise or alterations in GFAP and UCH-L1 levels independent of the TBI:
1. Spinal Cord Injury (radiological evidence)
2. A known central nervous system (CNS) and/or paraneoplastic malignancy.
3. Acute Kidney Injury (Creatinine levels greater than 1.5x baseline) or End-stage renal failure (receives chronic dialysis)
4. Pre-existing neurodegenerative disease (Parkinson’s, Alzheimer’s, Lewy body, etc.)
5. Cardiac arrest / suspected hypoxic-ischaemic encephalopathy.
6. Pregnancy/lactation/=3 months postpartum
7. Massive transfusion in the previous 12 hours

Conditions that may interefere with the ability to assess outcomes:
1. Severe pre-existing physical or mental disability or severe comorbidity that may interfere with the assessment of outcome.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,WA
Recruitment hospital [1] 29803 0
Royal Perth Hospital - Perth
Recruitment hospital [2] 29804 0
The Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 46149 0
6000 - Perth
Recruitment postcode(s) [2] 46150 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 322130 0
Charities/Societies/Foundations
Name [1] 322130 0
Perron Institute
Country [1] 322130 0
Australia
Primary sponsor type
Government body
Name
East Metropolitan Health Service
Address
Country
Australia
Secondary sponsor category [1] 325021 0
None
Name [1] 325021 0
Address [1] 325021 0
Country [1] 325021 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320658 0
WA Health Central HREC
Ethics committee address [1] 320658 0
Ethics committee country [1] 320658 0
Australia
Date submitted for ethics approval [1] 320658 0
13/05/2024
Approval date [1] 320658 0
06/06/2024
Ethics approval number [1] 320658 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151198 0
Dr Robert McNamara
Address 151198 0
Royal Perth Hospital, Intensive Care Unit, 197 Wellington Street, Perth, Western Australia 6000
Country 151198 0
Australia
Phone 151198 0
+61 8 8922 2244
Fax 151198 0
Email 151198 0
Contact person for public queries
Name 151199 0
Mia Cahill
Address 151199 0
Royal Perth Hospital, Intensive Care Unit, 197 Wellington Street, Perth, Western Australia 6000
Country 151199 0
Australia
Phone 151199 0
+61 8 9224 8118
Fax 151199 0
Email 151199 0
Contact person for scientific queries
Name 151200 0
Robert McNamara
Address 151200 0
Royal Perth Hospital, Intensive Care Unit, 197 Wellington Street, Perth, Western Australia 6000
Country 151200 0
Australia
Phone 151200 0
+61 8 8922 2244
Fax 151200 0
Email 151200 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.